The leading Australian CRO for biotechs, Avance Clinical, accepted the prestigious Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award at a global virtual awards ceremony overnight.
Full Service CRO
With strong co-existing relationships with all Phase 1 units across Australia.
Highly Experienced Team
Supporting our global client portfolio with over 20 years’ experience.
World class reputation for accuracy, precision and quality data sets.
THE AUSTRALIAN Advantage
The Australian Regulatory Framework is the fastest in the world for undertaking early phase clinical trials.
About Avance Clinical
At Avance Clinical, we have over 20 years’ experience in offering seamless end-to-end in-house clinical research services, supporting our global client portfolio with clinical project management, trial monitoring, local safety reporting, medical writing, data management, statistical and pharmacokinetic services, CDISC and external and internal auditing.
As a leading Australian CRO, with extensive experience across all phases of clinical research, complemented with our full suite of in-house clinical research services, we can ensure your trials are delivered on time and on budget as a certified contract research organisation.
Latest News & Events
Press Release: TrialTrove Data Shows Australia is Open for Business says Avance Clinical at BIO Digital 2020
Adelaide, Australia – The leading Australian CRO for biotechs, Avance Clinical announced at BIO Digital today that Australia currently has 2,413 trials planned or ongoing.
Importantly in Australia, despite the global COVID-19 pandemic, no healthy volunteer studies have been suspended, and only 27 Phase 1 or 2 studies were temporarily put on hold for various reasons (TrialTrove, 9 June 2020).
Premier of South Australia Steven Marshall Briefed on $50 billion Clinical Trial Sector During Visit to Adelaide-based Avance Clinical
The leading Australian CRO for biotechs, Avance Clinical, hosted a visit with the Premier of South Australia the Hon. Steven Marshall MP to discuss the fast-growing clinical trials sector, currently worth $50 billion and increasing to $71.7 billion by 2024 according to Frost & Sullivan.
As oncology sponsors look internationally to speed-up trials after unprecedented COVID-19 suspensions and delays, Australia, which has led the world in minimizing the pandemic’s impact, stands out as an attractive destination for early phase trials. This in combination with the streamlined regulatory system and the financial benefits including a very favourable exchange rate and the R & D cash rebate makes Australia the perfect location for accelerating biotech clinical programs.
A joint BiospectrumAsia and Avance Clinical special webinar featuring Gabriel KremmidiotisPhD, BSC Hon, Chief Scientific Officer Avance Clinical. Registration is now open CLICK HERE
Avance Clinical, which has been offering CRO services for more than two decades for early phase trials, reports 95 new trials were registered in the past 30 days as recorded in Australian and New Zealand registry ANZCTR.org.au Read the news article here